| Sep 19 |
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
|
| Sep 6 |
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
|
| Sep 5 |
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
|
| Sep 5 |
Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
|
| Aug 28 |
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
|
| Aug 27 |
Exploring Three High Growth Tech Stocks In The United States
|
| Aug 23 |
Arcutis surges 18% as Mizuho highlights growth of Zoryve
|
| Aug 22 |
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
|
| Aug 22 |
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 15 |
Q2 2024 Arcutis Biotherapeutics Inc Earnings Call
|
